论文部分内容阅读
自1991年3月至1997年12月，对14例不能手术的胆管癌进行了腔内近距离治疗，其中12例为肝门部胆管癌。腔内治疗采用高剂量率192Ir，剂量参考点距施源器中心轴的距离是10～12mm，参考点剂量为每次700～1000cGy，共3～5次。近距离照射总量为2800～4000cGy。治疗后的平均生存时间为11．2月。1、2、3、4年生存率分别为42．9％（6／14），33．3％（4／12），25．0％（2／8）和16．7％（1／6）、无严重的副反应。提示，腔内近距离治疗为不能手术切除的胆管癌提供了一种副作用小而疗效较好的治疗手段，提高了患者的生存质量，延长了生存时间。
From March 1991 to December 1997, 14 cases of inoperable cholangiocarcinoma were treated with intracavity brachytherapy, of which 12 cases were hilar cholangiocarcinoma. The endoluminal treatment uses a high dose rate of 192Ir. The distance from the dose reference point to the central axis of the applicator is 10 to 12mm, and the reference point dose is 700 to 1000cGy each, for a total of 3 to 5 times. The total amount of close-range irradiation is 2800 to 4000 cGy. The average survival time after treatment was 11.2 months. The 1-, 2-, 3-, and 4-year survival rates were 42.9% (6/14), 33.3% (4/12), 25.0% (2/8), and 16.7% (1/6, respectively). ) No serious side effects. It is suggested that intraluminal brachytherapy provides a treatment with less side effects and better curative effect for non-surgical cholangiocarcinoma, which improves the quality of life of patients and prolongs survival time.